Troglitazone corrects metabolic changes but not vascular dysfunction in dietary-obese rats

Area of Science:

• Endocrinology
• Vascular Biology
• Metabolic Syndrome

Background:

• Insulin resistance is linked to vascular dysfunction in obesity, type 2 diabetes, and dyslipidemia.
• Obesity is associated with significant metabolic disturbances and impaired blood vessel function.

Purpose of the Study:

• To investigate the vascular effects of chronic troglitazone administration in diet-induced obese female Wistar rats.
• To determine if troglitazone can ameliorate obesity-associated vascular dysfunction.

Main Methods:

• Chronic (3-week) administration of troglitazone to obese female Wistar rats.
• Assessment of metabolic parameters (body weight, fat mass, plasma lipids, leptin).
• Evaluation of mesenteric artery responses to vasoactive agents (noradrenaline, KCl, acetylcholine, insulin, sodium nitroprusside).

Main Results:

• Troglitazone corrected obesity-induced metabolic changes, including elevated body weight, fat mass, triglycerides, free fatty acids, and leptin.
• Vascular responses to acetylcholine and insulin were significantly attenuated in both untreated and troglitazone-treated obese rats compared to lean controls.
• Impairment in vasorelaxation to sodium nitroprusside was observed in obese rats, though less pronounced than with acetylcholine or insulin.

Conclusions:

• Troglitazone effectively improves metabolic parameters associated with obesity.
• Despite metabolic improvements, troglitazone failed to restore normal vascular function in obese rats.
• Obesity-induced vascular dysfunction may be resistant to correction by troglitazone, highlighting a persistent pathological mechanism.